ATG3 and cervical cancer: Figure 5(f) shows that circulating ATG3 had increased expression in cervical cancer plasma than normal specimens (p < 0.001). Correlation analysis revealed that miR-651 exhibited a negative interaction with ATG3 among cervical cancer subjects (p < 0.0001, r = −0.5188; Figure 5(g)).